title: Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
abstract: Progression of breast cancer to metastatic bone disease is linked to deregulated expression of the transcription factor Runx2. Therefore, our goal was to evaluate the potential for clinical use of Runx2-targeting miRNAs to reduce tumor growth and bone metastatic burden. Expression analysis of a panel of miRNAs regulating Runx2 revealed a reciprocal relationship between the abundance of Runx2 protein and two miRNAs, miR-135 and miR-203. These miRNAs are highly expressed in normal breast epithelial cells where Runx2 is not detected, and absent in metastatic breast cancer cells and tissue biopsies that express Runx2. Reconstituting metastatic MDA-MB-231-luc cells with miR-135 and miR-203 reduced the abundance of Runx2 and expression of the metastasis-promoting Runx2 target genes IL11, MMP-13, and PTHrP. In addition, tumor cell viability was decreased and migration suppressed in vitro. Orthotopic implantation of MDA-MB-231-luc cells delivered with miR-135 or miR-203, followed by an intratumoral administration of the synthetic miRNAs, reduced the tumor growth and spontaneous metastasis to bone. Furthermore, intratibial injection of these miRNA-delivered cells impaired tumor growth in the bone environment and inhibited bone resorption. Importantly, reconstitution of Runx2 in MDA-MB-231-luc cells delivered with miR-135 and miR-203 reversed the inhibitory effect of the miRNAs on tumor growth and metastasis. Thus, we have identified that aberrant expression of Runx2 in aggressive tumor cells is related to the loss of specific Runx2-targeting miRNAs and that a clinically relevant replacement strategy by delivery of synthetic miRNAs is a candidate for a therapeutic approach to prevent metastatic bone disease by this route.
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts. Heisenberg-Group for Molecular Skeletal Biology, Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. jane.lian@uvm.edu h.taipaleenmaeki@uke.de.
authors: Hanna
authors: H
authors: Taipaleenmäki
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts. Department of Biochemistry and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont.
authors: Gillian
authors: G
authors: Browne
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts.
authors: Jacqueline
authors: J
authors: Akech
authors: Gerhard Domagk Institute of Pathology, University of Münster, Münster, Germany.
authors: Jozef
authors: J
authors: Zustin
authors: Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
authors: Andre J
authors: AJ
authors: van Wijnen
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts. Department of Biochemistry and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont.
authors: Janet L
authors: JL
authors: Stein
authors: Heisenberg-Group for Molecular Skeletal Biology, Department of Trauma, Hand & Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
authors: Eric
authors: E
authors: Hesse
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts. Department of Biochemistry and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont.
authors: Gary S
authors: GS
authors: Stein
authors: Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts. Department of Biochemistry and Vermont Cancer Center, University of Vermont College of Medicine, Burlington, Vermont. jane.lian@uvm.edu h.taipaleenmaeki@uke.de.
authors: Jane B
authors: JB
authors: Lian
mesh_terms: D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000502:physiology; D001859:Bone Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000556:secondary; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D050659:Core Binding Factor Alpha 1 Subunit / Q000235:genetics* / Q000378:metabolism; D018450:Disease Progression; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016513:Mice, SCID; D035683:MicroRNAs / Q000235:genetics*; D009368:Neoplasm Transplantation; D034622:RNA Interference
chemical_list: D019485:Bone Morphogenetic Proteins; D050659:Core Binding Factor Alpha 1 Subunit; C544965:MIRN135 microRNA, human; C546703:MIRN203 microRNA, human; D035683:MicroRNAs; C493709:RUNX2 protein, human
references: Nat Rev Cancer. 2002 Aug;2(8):584-93
references: 12154351
references: Mol Cell Biol. 2005 Oct;25(19):8581-91
references: 16166639
references: Oncogene. 2010 Feb 11;29(6):811-21
references: 19915614
references: Nat Rev Endocrinol. 2012 Apr;8(4):212-27
references: 22290358
references: Oncogene. 2008 Oct 23;27(49):6322-33
references: 18663362
references: Cancer Res. 2009 Sep 1;69(17):6807-14
references: 19690135
references: Nucleic Acids Res. 2009 Jan;37(Database issue):D925-32
references: 18927105
references: Nature. 2014 Aug 28;512(7515):431-5
references: 25043055
references: Curr Osteoporos Rep. 2013 Jun;11(2):72-82
references: 23605904
references: N Engl J Med. 2004 Apr 15;350(16):1655-64
references: 15084698
references: Bone. 2011 Jan;48(1):30-6
references: 20561908
references: Cancer Res. 2011 May 1;71(9):3257-67
references: 21505104
references: Trends Endocrinol Metab. 2014 Jun;25(6):320-7
references: 24811921
references: Nat Biotechnol. 2013 Jul;31(7):577
references: 23839128
references: Genes Cancer. 2011 Aug;2(8):782-91
references: 22393463
references: EMBO Mol Med. 2012 Mar;4(3):143-59
references: 22351564
references: Cancer Res. 2008 Oct 1;68(19):7795-802
references: 18829534
references: Bone. 2011 Jan;48(1):23-9
references: 20699127
references: Eur J Endocrinol. 2012 Mar;166(3):359-71
references: 22084154
references: Breast Cancer Res. 2010;12(5):R89
references: 21029421
references: Eur J Cancer. 2009 Sep;45(13):2239-48
references: 19632824
references: Mol Cancer. 2012;11:66
references: 22966907
references: Bone. 2011 Jan;48(1):16-22
references: 20630490
references: Cell Cycle. 2011 Apr 1;10(7):1121-31
references: 21368580
references: J Biol Chem. 2013 Jul 19;288(29):21307-19
references: 23720736
references: J Biol Chem. 2013 Apr 12;288(15):10241-53
references: 23447531
references: Nat Med. 2013 Jan;19(1):93-100
references: 23223004
references: Clin Cancer Res. 2011 Aug 15;17(16):5287-98
references: 21159887
references: Mol Ther. 2010 Jan;18(1):181-7
references: 19738602
references: Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9863-8
references: 21628588
references: Lab Invest. 2012 Aug;92(8):1181-90
references: 22641097
references: Nat Rev Cancer. 2011 Jun;11(6):411-25
references: 21593787
references: J Clin Invest. 1999 Jan;103(2):197-206
references: 9916131
references: Cancer Cell. 2013 Oct 14;24(4):542-56
references: 24135284